• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    1/10/24 8:05:53 AM ET
    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email

    Gainers

    • Exicure (NASDAQ:XCUR) stock increased by 29.8% to $0.8 during Wednesday's pre-market session. The company's market cap stands at $6.9 million.
    • Telesis Bio (NASDAQ:TBIO) shares moved upwards by 21.88% to $0.46. The market value of their outstanding shares is at $13.6 million.
    • Jin Medical International (NASDAQ:ZJYL) shares moved upwards by 21.33% to $110.0. The company's market cap stands at $852.5 million.
    • Estrella Immunopharma (NASDAQ:ESLA) stock increased by 15.78% to $1.1. The company's market cap stands at $38.7 million.
    • Amarin Corp (NASDAQ:AMRN) shares increased by 15.35% to $1.12. The market value of their outstanding shares is at $457.2 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 12.99% to $0.6. The company's market cap stands at $7.3 million.

    Losers

    • Aclaris Therapeutics (NASDAQ:ACRS) shares fell 14.1% to $1.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $77.9 million.
    • Forian (NASDAQ:FORA) stock decreased by 9.93% to $2.54. The market value of their outstanding shares is at $78.6 million.
    • Veradigm (NASDAQ:MDRX) stock decreased by 9.86% to $9.7. The market value of their outstanding shares is at $1.0 billion.
    • cbdMD (AMEX:YCBD) stock decreased by 8.87% to $0.85. The company's market cap stands at $2.5 million.
    • ThermoGenesis Holdings (NASDAQ:THMO) stock decreased by 8.58% to $0.46. The market value of their outstanding shares is at $1.4 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares declined by 8.32% to $0.58. The company's market cap stands at $20.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $AMRN
    $BPTH
    $ESLA

    CompanyDatePrice TargetRatingAnalyst
    Aclaris Therapeutics Inc.
    $ACRS
    7/10/2025$6.00Overweight
    Piper Sandler
    Aclaris Therapeutics Inc.
    $ACRS
    5/28/2025$8.00Outperform
    Wedbush
    Aclaris Therapeutics Inc.
    $ACRS
    3/18/2025Overweight
    Cantor Fitzgerald
    Aclaris Therapeutics Inc.
    $ACRS
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    Aclaris Therapeutics Inc.
    $ACRS
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    Aclaris Therapeutics Inc.
    $ACRS
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    Aclaris Therapeutics Inc.
    $ACRS
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    Aclaris Therapeutics Inc.
    $ACRS
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hitron Systems Inc. bought $8,700,000 worth of shares (2,900,000 units at $3.00), increasing direct ownership by 669% to 3,333,333 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    3/26/25 5:41:19 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exec Chairman, CEO & President Wygod Max C bought $2,605 worth of shares (880 units at $2.96), increasing direct ownership by 0.07% to 1,328,927 units (SEC Form 4)

    4 - Forian Inc. (0001829280) (Issuer)

    2/18/25 7:56:28 PM ET
    $FORA
    EDP Services
    Technology

    Exec Chairman, CEO & President Wygod Max C bought $42,249 worth of shares (15,867 units at $2.66), increasing direct ownership by 1% to 1,328,047 units (SEC Form 4)

    4 - Forian Inc. (0001829280) (Issuer)

    2/13/25 9:30:24 PM ET
    $FORA
    EDP Services
    Technology

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    SEC Filings

    View All

    SEC Form 8-K filed by Aclaris Therapeutics Inc.

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    3/11/26 4:30:11 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    3/9/26 9:51:15 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by cbdMD Inc.

    EFFECT - cbdMD, Inc. (0001644903) (Filer)

    3/5/26 12:15:15 AM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

    DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology's Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA. Featured Amarin-supported abstracts to be presented by academic collaborators (italicized below) at ACC Scientific Sessions 2026 include: Oral Presentation Efficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular

    3/16/26 8:15:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jin Medical International Ltd. Announces 1-for-20 Share Combination as Part of Strategic Nasdaq Compliance Initiative

    CHANGZHOU, China, March 11, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries and consolidated entities, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that its Board of Directors has approved an 1-for-20 share combination of all its authorized and issued ordinary shares (the "Stock Combination") pursuant to the authorization granted from an extraordinary general meeting of the Company's shareholders on January 30, 2026 (the "EGM"). Effective as of the date of the EGM, the Company's authorized share capital is reclassified into a dual class of Class A ordinary shares

    3/11/26 7:30:00 PM ET
    $ZJYL
    Industrial Specialties
    Health Care

    Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

    WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcasts will be available on the Aclaris website for at least 30 days. About

    3/3/26 7:00:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Aclaris Therapeutics with a new price target

    Piper Sandler resumed coverage of Aclaris Therapeutics with a rating of Overweight and set a new price target of $6.00

    7/10/25 8:47:17 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Aclaris Therapeutics with a new price target

    Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/28/25 8:54:54 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

    Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

    3/18/25 8:23:58 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Balthaser Kevin converted options into 2,375 shares and covered exercise/tax liability with 677 shares, increasing direct ownership by 0.91% to 187,453 units (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    3/3/26 4:10:13 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Vesey Michael covered exercise/tax liability with 4,918 shares, decreasing direct ownership by 0.83% to 589,610 units (SEC Form 4)

    4 - Forian Inc. (0001829280) (Issuer)

    2/18/26 9:33:28 PM ET
    $FORA
    EDP Services
    Technology

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer

    Healthcare IT Veteran - former AWS and Cerner senior executive - to lead and accelerate innovation across Veradigm's unique footprint Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today appoints Tehsin Syed, a healthcare technology leader with over two decades of experience, as Chief Product and Technology Officer. Syed most recently served as General Manager, AWS Health AI (Amazon Web Services). Under his leadership, the organization scaled as a growth engine, with net-new products for ambient clinical documentation, genomics, and medical imaging, and interoperability elevated to enterprise grade - capabilities trusted by providers, payers, bioph

    11/3/25 4:01:00 PM ET
    $MDRX
    EDP Services
    Technology

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Aclaris Therapeutics Announces Leadership Transition

    - Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as Special Scientific Advisor to the Chief Executive Officer through March 2026 as Part of Planned Retirement - WAYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer, replacing Joe Monahan, Ph.D. who will remain with the Company as Special Scientific Advisor to the Chief Executive Officer through the first quarter of 2026 as

    7/28/25 8:45:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Financials

    Live finance-specific insights

    View All

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amarin Reports Fourth Quarter and Full Year 2025 Financial Results

    Strategic Initiatives and Refined Business Model Produced Financial and Operating Efficiencies Established Long-Term License and Supply Agreement to Commercialize VAZKEPA® Across Europe and Sustained U.S. Market Leadership for VASCEPA® Franchise Total of 45 Publications (Abstracts, Posters, Manuscripts) Furthering the Expansion of the VASCEPA® /VAZKEPA® (icosapent ethyl) Body of Knowledge Supported in 2025 DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced financial results for the fourth quarter and full year ended December 31, 20

    2/25/26 7:00:00 AM ET
    $AMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    cbdMD Reports Sequential Revenue Growth, Improved Liquidity, and Strong Start to Fiscal 2026

    CHARLOTTE, N.C., Feb. 17, 2026 /PRNewswire/ -- cbdMD, Inc. (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD, Bluebird Botanicals, Paw CBD, along with its THC beverage brand Oasis today announced its financial results for the first quarter of fiscal year ended December 31, 2025. cbdMD reported 12% sequential revenue growth and improved liquidity in the first quarter of fiscal 2026, reflecting continued stabilization of the core business and early benefits from recent strategic actions."We a

    2/17/26 4:10:00 PM ET
    $YCBD
    Package Goods/Cosmetics
    Consumer Discretionary

    $ACRS
    $AMRN
    $BPTH
    $ESLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care